Methotrexate significantly lowers systolic blood pressure in newly diagnosed RA patients compared to sulfasalazine, potentially reducing cardiovascular risk. The study provides prospective comparative ...

Methotrexate, a common medication used to treat rheumatoid arthritis, has a newly recognised useful secondary effect to lower blood pressure and potentially reduces the risk of heart disease in people ...

Disease-modifying drug therapies are being sought intensively for osteoarthritis (OA), but none have proved out thus far. A previous trial in patients with OA of the hand had found that methotrexate ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...

(RTTNews) - Sandoz (SDZNY) has initiated an antitrust lawsuit in the United States against Amgen, Inc. (AMGN), accusing the company of maintaining its dominant market position for the blockbuster drug ...

Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301) R1 compared induction ...

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer JCOG0905 is a multicenter, open-label, multi-institutional, randomized trial ...

Researchers develop targeted polymersomes to enhance methotrexate delivery, offering a promising new approach for treating aggressive choriocarcinoma. Study: ENT-1-Targeted Polymersomes to Enhance the ...

Methotrexate is a generic drug prescribed to treat certain types of cancers, arthritis, and psoriasis in adults and some children. As with other drugs, methotrexate can cause side effects, such as ...

Please provide your email address to receive an email when new articles are posted on . In 2026, Stelara will be discounted 66% from its list price for Medicare users, while Enbrel will be discounted ...

In July 2022, the US Food and Drug Administration (FDA) expanded the labeling of Krystexxa (pegloticase; Horizon Therapeutics), a PEGylated uric acid-specific enzyme, to include coadministration with ...

A drugmaker whose product could be the first subjected to a price cap in Colorado is suing to throw out the state board that deemed its medication unaffordable. In February, the Colorado Prescription ...